A recent study concludes that both hypertension and proteinuria, which are considered to be interrelated with the pharmacological action of bevacizumab, have the potential to indicate greater likelihood of therapeutic efficacy.
Bevacizumab, an anti-vascular endothelial growth factor (anti-VEGF) treatment, can be used in combination with paclitaxel to treat advanced breast cancer, but hypertension and proteinuria are characteristic adverse events (AEs) associated with bevacizumab therapy. A proposed mechanism underlying bevacizumab-induced hypertension is the inhibition of VEGF, which results in decreased production of the vasodilator nitric oxide. Development of proteinuria has also been attributed to VEGF inhibition, which can decrease glomerular filtration and lead to protein leakage into urine.
A recent study in Japanese patients with breast cancer investigated whether these AEs could serve as predictors of treatment response to bevacizumab, and found that patients who developed hypertension and proteinuria early in their therapy had a stronger antitumor response.
The retrospective study, published in the Biological and Pharmaceutical Bulletin, included 19 patients with advanced, recurrent breast cancer treated in a single center in Japan between May 2012 to January 2016. Patients were observed from the beginning of therapy to 8 weeks after. During the observation period, 7 patients developed hypertension during the study period, while 12 did not; 7 patients developed proteinuria, and 12 did not.
No patients achieved a complete response, but in the group that developed hypertension, 100% achieved a partial response (PR), while 33.3% of the non-hypertensive group achieved a PR. Similarly, 100% of the group who developed proteinuria and 33.3% of the group who did not achieved a PR. According to the authors, these findings demonstrate a significantly stronger antitumor response in the 2 AE groups (P <.05).
Median progression-free survival (PFS) in the groups with and without hypertension were 355 days versus 147 days, respectively; median PFS for patients with and without proteinuria were 504 days versus 173 days, respectively.
The authors conclude that both hypertension and proteinuria, which are considered to be interrelated with the pharmacological action of bevacizumab, have the potential to indicate greater likelihood of therapeutic efficacy.
In order to control these AEs so that therapy can continue, say the authors, patients may need to be given appropriate antihypertensive medication. Proteinuria can, when of a high grade, require discontinuation of bevacizumab; however, the authors say that patients may continue to benefit from bevacizumab even after treatment discontinuation.
Reference
Tanaka H, Takahashi K, Yamaguchi K, et al. Hypertension and proteinuria as predictive factors of effects on bevacizumab on advanced breast cancer in Japan. Biol Pharm Bull. 2018;41(4):644-648. doi: 10.1248/bpb.b17-00605.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.